Godau, BrentSamimi, SadafSeyfoori, AmirSamiei, EhsanKhani, TaherehNaserzadeh, ParvanehNajafabadi, Alireza HassaniLesha, EmalMajidzadeh-A, KeivanAshtari, BehnazCharest, GabrielMorin, ChristopheFortin, DavidAkbari, Mohsen2024-01-242024-01-2420232023Godau, B., Samimi, S., Seyfoori, A., Samiei, E., Khani, T., Naserzadeh, P., Najafabadi, A. H., Lesha, E., Majidzadeh-A, K., Ashtari, B., Charest, G., Morin, C., Fortin, D., & Akbari, M. (2023). A drug-eluting injectable nanogel for localized delivery of anticancer drugs to solid tumors. Pharmaceutics, 15(9), 2255. https://doi.org/10.3390/pharmaceutics15092255https://doi.org/10.3390/pharmaceutics15092255http://hdl.handle.net/1828/15871Systemically administered chemotherapy reduces the efficiency of the anticancer agent at the target tumor tissue and results in distributed drug to non-target organs, inducing negative side effects commonly associated with chemotherapy and necessitating repeated administration. Injectable hydrogels present themselves as a potential platform for non-invasive local delivery vehicles that can serve as a slow-releasing drug depot that fills tumor vasculature, tissue, or resection cavities. Herein, we have systematically formulated and tested an injectable shear-thinning hydrogel (STH) with a highly manipulable release profile for delivering doxorubicin, a common chemotherapeutic. By detailed characterization of the STH physical properties and degradation and release dynamics, we selected top candidates for testing in cancer models of increasing biomimicry. Two-dimensional cell culture, tumor-on-a-chip, and small animal models were used to demonstrate the high anticancer potential and reduced systemic toxicity of the STH that exhibits long-term (up to 80 days) doxorubicin release profiles for treatment of breast cancer and glioblastoma. The drug-loaded STH injected into tumor tissue was shown to increase overall survival in breast tumor- and glioblastoma-bearing animal models by 50% for 22 days and 25% for 52 days, respectively, showing high potential for localized, less frequent treatment of oncologic disease with reduced dosage requirements.enlocalized therapyshear-thinning hydrogelcancer therapyglioblastomabreast cancerArticleDepartment of Mechanical Engineering